Liver Disease Treatment Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Liver Disease Treatment Market Overview – 8 Major Markets  
    3.1    Liver Disease Treatment Market Historical Value (2017-2023) 
    3.2    Liver Disease Treatment Market Forecast Value (2024-2032) 
4    Vendor  Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Liver Disease Treatment Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Treatment Pathway 
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Treatment Success Rate
7    Liver Disease Treatment Market - Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    United States 
            7.1.1.2    United Kingdom
            7.1.1.3    EU4
            7.1.1.4    India
            7.1.1.5    Japan
        7.1.2    Diagnosed Cases, by Country
            7.1.2.1    United States 
            7.1.2.2    United Kingdom
            7.1.2.3    EU4
            7.1.2.4    India
            7.1.2.5    Japan
        7.1.3    Treatment Seeking Rate, by Country 
            7.1.3.1    United States 
            7.1.3.2    United Kingdom
            7.1.3.3    EU4
            7.1.3.4    India
            7.1.3.5    Japan
8    Liver Disease Treatment Market Landscape – 8 Major Markets 
    8.1    Liver Disease Treatment Market: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2    Liver Disease Treatment Market: Product Landscape
        8.2.1    Analysis by Treatment Type 
        8.2.2    Analysis by Disease Type
9    Liver Disease Treatment Market Challenges and Unmet Needs
    9.1    Treatment Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Treatment
11    Liver Disease Treatment Market Dynamics
    11.1    Market Drivers and Constraints
    11.2    SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3    PESTEL Analysis
        11.3.1    Political
        11.3.2    Economic
        11.3.3    Social
        11.3.4    Technological
        11.3.5    Legal
        11.3.6    Environment
    11.4    Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5    Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends  
    11.8    Value Chain Analysis
12    Liver Disease Treatment Market Segmentation (2017-2032) - 8 Major Markets 
    12.1    Liver Disease Treatment Market (2017-2032) by Treatment Type
        12.1.1    Market Overview    
        12.1.2    Antiviral Drugs
        12.1.3    Immunosuppressants
        12.1.4    Vaccines
        12.1.5    Corticosteroids
        12.1.6    Immunoglobins
        12.1.7    Targeted Therapy
        12.1.8    Chemotherapy
        12.1.9    Others
    12.2    Liver Disease Treatment Market (2017-2032) by Disease Type
        12.2.1    Market Overview
        12.2.2    Hepatitis
        12.2.3    Autoimmune Diseases
        12.2.4    Non-alcoholic fatty Liver Disease
        12.2.5    Cancer
        12.2.6    Others
    12.3    Liver Disease Treatment Market (2017-2032) by End User
        12.3.1    Market Overview
        12.3.2    Hospital and Clinics
        12.3.3    Diagnostic Centers
        12.3.4    Others
    12.4    Liver Disease Treatment Market (2017-2032) by Region
        12.4.1    Market Overview
        12.4.2    United States
        12.4.3    EU-4 and the United Kingdom
            12.4.3.1    Germany
            12.4.3.2    France
            12.4.3.3    Italy
            12.4.3.4    Spain
            12.4.3.5    United Kingdom
        12.4.4    Japan
        12.4.5    India 
13    United States Liver Disease Treatment Market (2017-2032)
    13.1    United States Liver Disease Treatment Market Historical Value (2017-2023) 
    13.2    United States Liver Disease Treatment Market Forecast Value (2024-2032)
    13.3    United States Liver Disease Treatment Market (2017-2032) by Treatment Type
        13.3.1    Market Overview    
        13.3.2    Antiviral Drugs
        13.3.3    Immunosuppressants
        13.3.4    Vaccines
        13.3.5    Corticosteroids
        13.3.6    Immunoglobins
        13.3.7    Targeted Therapy
        13.3.8    Chemotherapy
        13.3.9    Others
    13.4    United States Liver Disease Treatment Market (2017-2032) by Disease Type
        13.4.1    Market Overview
        13.4.2    Hepatitis
        13.4.3    Autoimmune Diseases
        13.4.4    Non-alcoholic fatty Liver Disease
        13.4.5    Cancer
        13.4.6    Others
    13.5    United States Liver Disease Treatment Market (2017-2032) by End User
        13.5.1    Market Overview
        13.5.2    Hospital and Clinics
        13.5.3    Diagnostic Centers
        13.5.4    Others
14    EU-4 and United Kingdom Liver Disease Treatment Market (2017-2032)
    14.1    EU-4 and United Kingdom Liver Disease Treatment Market Historical Value (2017-2023) 
    14.2    EU-4 and United Kingdom Liver Disease Treatment Market Forecast Value (2024-2032)
    14.3    EU-4 and United Kingdom Liver Disease Treatment Market (2017-2032) by Treatment Type
        14.3.1    Market Overview    
        14.3.2    Antiviral Drugs
        14.3.3    Immunosuppressants
        14.3.4    Vaccines
        14.3.5    Corticosteroids
        14.3.6    Immunoglobins
        14.3.7    Targeted Therapy
        14.3.8    Chemotherapy
        14.3.9    Others
    14.4    EU-4 and United Kingdom Liver Disease Treatment Market (2017-2032) by Disease Type
        14.4.1    Market Overview
        14.4.2    Hepatitis
        14.4.3    Autoimmune Diseases
        14.4.4    Non-alcoholic fatty Liver Disease
        14.4.5    Cancer
        14.4.6    Others
    14.5    EU-4 and United Kingdom Liver Disease Treatment Market (2017-2032) by End User
        14.5.1    Market Overview
        14.5.2    Hospital and Clinics
        14.5.3    Diagnostic Centers
        14.5.4    Others
15    Japan Liver Disease Treatment Market
    15.1    Japan Liver Disease Treatment Market Historical Value (2017-2023) 
    15.2    Japan Liver Disease Treatment Market Forecast Value (2024-2032)
    15.3    Japan Liver Disease Treatment Market (2017-2032) by Treatment Type
        15.3.1    Market Overview    
        15.3.2    Antiviral Drugs
        15.3.3    Immunosuppressants
        15.3.4    Vaccines
        15.3.5    Corticosteroids
        15.3.6    Immunoglobins
        15.3.7    Targeted Therapy
        15.3.8    Chemotherapy
        15.3.9    Others
    15.4    Japan Liver Disease Treatment Market (2017-2032) by Disease Type
        15.4.1    Market Overview
        15.4.2    Hepatitis
        15.4.3    Autoimmune Diseases
        15.4.4    Non-alcoholic fatty Liver Disease
        15.4.5    Cancer
        15.4.6    Others
    15.5    Japan Liver Disease Treatment Market (2017-2032) by End User
        15.5.1    Market Overview
        15.5.2    Hospital and Clinics
        15.5.3    Diagnostic Centers
        15.5.4    Others
16    India Liver Disease Treatment Market
    16.1    India Liver Disease Treatment Market (2017-2032) Historical Value (2017-2023) 
    16.2    India Liver Disease Treatment Market (2017-2032) Forecast Value (2024-2032)
    16.3    India Liver Disease Treatment Market (2017-2032) by Treatment Type
        16.3.1    Market Overview    
        16.3.2    Antiviral Drugs
        16.3.3    Immunosuppressants
        16.3.4    Vaccines
        16.3.5    Corticosteroids
        16.3.6    Immunoglobins
        16.3.7    Targeted Therapy
        16.3.8    Chemotherapy
        16.3.9    Others
    16.4    India Liver Disease Treatment Market (2017-2032) by Disease Type
        16.4.1    Market Overview
        16.4.2    Hepatitis
        16.4.3    Autoimmune Diseases
        16.4.4    Non-alcoholic fatty Liver Disease
        16.4.5    Cancer
        16.4.6    Others
    16.5    India Liver Disease Treatment Market (2017-2032) by End User
        16.5.1    Market Overview
        16.5.2    Hospital and Clinics
        16.5.3    Diagnostic Centers
        16.5.4    Others
17    Regulatory Framework
    17.1    Regulatory Overview
    17.2    US FDA
    17.3    EU EMA
    17.4    Japan PMDA
    17.5    India CDSCO
    17.6    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication Year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation
19    Clinical Trials Analysis
    19.1    Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Grants Analysis
    20.1    Analysis by Year
    20.2    Analysis by Amount Awarded
    20.3    Analysis by Issuing Authority
    20.4    Analysis by Grant Application
    20.5    Analysis by Funding Institute
    20.6    Analysis by NIH Departments
    20.7    Analysis by Recipient Organization 
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Treatment Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Strategic Initiatives
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Treatment Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Market Share by Top 5 Companies
    23.2    Abbott Laboratories 
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Company News and Development
        23.2.5    Certifications
    23.3    Astellas Pharma Inc. 
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Company News and Development
        23.3.5    Certifications
    23.4    Bristol- Myers Squibb Company 
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Company News and Development
        23.4.5    Certifications
    23.5    Gilead Sciences 
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Company News and Development
        23.5.5    Certifications
    23.6    GlaxoSmithKline PLC 
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Company News and Development
        23.6.5    Certifications
    23.7    F. Hoffmann-La Roche Ltd. 
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Company News and Development
        23.7.5    Certifications
    23.8    Merck & Co., Inc. 
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Company News and Development
        23.8.5    Certifications
    23.9    Novartis AG 
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Company News and Development
        23.9.5    Certifications
    23.10    Sanofi AG 
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Company News and Development
        23.10.5    Certifications
    23.11    AbbVie Inc. 
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Company News and Development
        23.11.5    Certifications
    23.12    Pfizer Inc. 
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Company News and Development
        23.12.5    Certifications
24    Liver Disease Treatment Treatment Drugs - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.